2. Academic Validation
  3. Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes

Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes

  • J Neuroinflammation. 2014 Feb 27:11:37. doi: 10.1186/1742-2094-11-37.
Peter J Crack 1,  Moses Zhang,  Maria Cristina Morganti-Kossmann,  Andrew J Morris,  Jonathan M Wojciak,  Jonathan K Fleming,  Ila Karve,  David Wright,  Maithili Sashindranath,  Yona Goldshmit,  Alison Conquest,  Maria Daglas,  Leigh A Johnston,  Robert L Medcalf,  Roger A Sabbadini,  Alice Pébay
Affiliations

Affiliation

  • 1 Department of Pharmacology, the University of Melbourne, Parkville, Australia. pcrack@unimelb.edu.au.
PMID: 24576351 DOI: 10.1186/1742-2094-11-37
Abstract

Background: Lysophosphatidic acid (LPA) is a bioactive phospholipid with a potentially causative role in neurotrauma. Blocking LPA signaling with the LPA-directed monoclonal antibody B3/Lpathomab is neuroprotective in the mouse spinal cord following injury.

Findings: Here we investigated the use of this agent in treatment of secondary brain damage consequent to traumatic brain injury (TBI). LPA was elevated in cerebrospinal fluid (CSF) of patients with TBI compared to controls. LPA levels were also elevated in a mouse controlled cortical impact (CCI) model of TBI and B3 significantly reduced lesion volume by both histological and MRI assessments. Diminished tissue damage coincided with lower brain IL-6 levels and improvement in functional outcomes.

Conclusions: This study presents a novel therapeutic approach for the treatment of TBI by blocking extracellular LPA signaling to minimize secondary brain damage and neurological dysfunction.

Figures
Products